Lv3
300 积分 2025-06-10 加入
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation
7天前
已完结
Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea
7天前
已完结
Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population
7天前
已完结
One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study
7天前
已完结
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US
8天前
已完结
Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease—Estimating the True Value
8天前
已完结
Looming Crisis of Financial Toxicity in Neurologic Drug Pricing
1个月前
已完结
Can Pandemic Preparedness Benefit from Health-Economic Modelling? The Case for Nipah Virus
3个月前
已完结
Theoretical analysis of a fractional-order nipah virus transmission system with sensitivity and cost-effectiveness analysis
3个月前
已关闭
Disadvantaging Rivals: Vertical Integration in the Pharmaceutical Market
5个月前
已完结
皖公网安备34019202002308
